Small Molecule Drug
AnnJi Pharmaceutical Co., Ltd.
Pipelines & Platforms
- Clinical-Stage Focus: IND-enabling to
clinical proof of concept - Core Pipelines: Key assets include AJ201 (Kennedy’s Disease), HDAC6 inhibitor for neuropathy and fibrotic disease
- Therapeutic Areas: Neurology,
dermatology, and rare diseases - Value Driver: Translating pre-clinical research to clinical validation
Interests
- Out-Licensing
- Co-Development
- In-Licensing
- Strategic Alliance
Contact Information
- NameElvis Yang
- PositionAssociate Director, Business Development
- Tel+886-2-2365-5677 #301
- Emailelvis.yang@ajpharm.com
- https://www.ajpharm.com